Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12 Tips for Traveling With Diabetes
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
Latest
Popular
Top Rated
Insulin Injection Archives
Print | Email | Share | Comments (0)

Lipodystrophy Patients Benefit From Amylin Drug


Jul 24, 2011

Six-Month Lipodystrophy Study

Patients who have partial lipodystrophy, a condition that often leads to diabetes and high triglycerides, are benefiting from metreleptin, an investigational treatment being developed by Amylin Pharmaceuticals.

In a six-month study that involved nine patients with partial lipodystrophy, Amylin found that the drug, an analog of the hormone leptin, produced substantial results: The patients' mean baseline A1c of 8.1% dropped to 6.8% by the end of the study and was sustained through 15 months. Their triglyceride concentrations fell from a baseline measure of 318 mg/dL to 169 mg/dL at 15 months. Patients taking insulin saw their daily dose drop by 110 units.

Lipodystrophy patients have an abnormally low amount of fat tissue. Because leptin is secreted by fat cells, this creates a leptin deficiency.
Lack of leptin can lead to such metabolic disorders as extreme insulin resistance, high triglyceride levels, full-blown diabetes, and excessive liver fat.

The development of metreleptin as a supplement to diabetes drugs, special diets, and lipid-lowering drugs is welcome news for the estimated several thousand lipodystrophy patients worldwide. Currently, according to Amylin, 150 patients globally are receiving the drug.

The company hopes to complete submission of a request for approval to manufacture the drug to the FDA by the end of 2011.  Amylin presented the results of its study in early June at the 93rd Annual Meeting and Expo of the Endocrine Society in Boston.

 


Categories: Complications & Care, Diabetes, Diabetes, Insulin, Insulin Injection, Medications, Pharmaceutical Market /Products



You May Also Be Interested In...


Comments


Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.

When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.

For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.

Don't have your Diabetes Health Username? Register now and add your comments to all our content.

Have Your Say...


Username: Password:
Comment:
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.